Kliniken & Institute … Interdisziplinäre… Liver Cancer Center… Research Clinical studies

Clinical studies


NameSponsorObject of studyPhaseEntityStage
PROMETHEUSIITPhase I study evaluating the treatment of patients with advanced hepatocellular carcinoma (HCC) with Carbon Ion Radiotherapy1HCClocally advanced
CRUSH IIClamp-crushing vs. Stapler hepatectomyHCCresectable HCC
CFGF401X2101NovartisPhase I/II Study with FGF401 in patients with hepatocellular carcinoma or solid tumors characterized by positive FGFR4- and KLB-expression1/2HCC/CCpalliative second line
ACTICCA-1AIO/UKEAdjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) 3CCpalliative second line
MK 3475 224Merck/MSDPembrolizumab2HCCpalliative therapy, second line
MK 3475-240Merck/MSDPembrolizumab vs. BSC3HCCpalliative therapy, second line


recruitment closed

NameSponsorObject of studyPhaseEntityStage
MIRACLE ICeloNova BioSciences, Inc.Microparticle Enhanced Cytotoxic Transarterial Embolization Therapy in Hepatocellular Carcinoma (MIRACLE I)3HCCpalliative therapy, locally advanced
CA209-040BMSA Phase I Dose Escalation Study of Anti-Programmed-Death-1 (PD-1) Antibody (BMS-936558) in Advanced Hepatocellular Carcinoma1/2HCCpalliative therapy, first line
CIDH305X2101NovartisIDH305 for patients with relapsed glioma, AML or CC with IDH1-mutated1CCpalliative second line
OncosorbBioPheresis GmbHClinical Study of OncoSorb® in Patients With Advanced Cancer Entities (BP-005)1HCCpalliative therapy, last-line (solid tumors)
AMG 386amgenA Study of the Effectiveness and Safety of AMG 386 and Sorafenib to Treat Advanced or Inoperable Hepatocellular Cancer2HCCpalliative therapy, first line
HeiLivCaIITTACE +/- Sorafenib3HCCneoadjuvant therapy before LTx
CetuGEXGlycotope GmbHCetuGEX™ in Comparison to Cetuximab for the Treatment of Patients With Head and Neck Cancer (RESGEX)1HCCpalliative therapy last-line (solid tumors)
SHELTERPhase II trial evaluating resminostat in advanced hepatocellular carcinoma (HCC)2HCCpalliative therapy, second line (after Sorafenib)
GATHERRocheA Study of RO5137382 (GC33) in Patients With Advanced or Metastatic Hepatocellular Carcinoma2HCCpalliative therapy, second line (after Sorafenib)
BIBF 1120Boehringer-IngelheimPhase I/II Comparison of Efficacy and Safety of BIBF 1120 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma1/2HCCpalliative therapy, first line
INSIGHTBayerINSIGHT - Post Marketing Surveillance (INSIGHT)4HCCpalliative therapy, first line
SPACEBayerA Phase II Randomized, Double-blind, Placebo-controlled Study of Sorafenib or Placebo in Combination With Transarterial Chemoembolization (TACE) Performed With DC Bead and Doxorubicin for Intermediate Stage Hepatocellular Carcinoma (HCC).3HCClocally advanced
SOCSMedImmune LLCMEDI-573 in Combination With SOC in Unresectable or Metastatic HCC. (MEDI-573-1028)2HCCpalliative therapy, first line
TRAVERSEJenerexA Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed Sorafenib (TRAVERSE)2bHCCpalliative therapy, second line (after Sorafenib)
BAY86-9766BayerRefametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)2HCCpalliative therapy, Kras-mutated patients
PICCAIITCis/Gem vs. CIS/Gem + PanitumumabCC
ARQ197-A-U303DAIICHI SANKYO PHARMAStudy of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma Who Have Been Treated With One Prior Therapy (METIV-HCC)3HCCpalliative therapy, second line (after Sorafenib)
E7080-G000-304EisaiA Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-Line Treatment of Subjects With Unresectable Hepatocellular Carcinoma3HCCpalliative therapy, first line
CBGJ398X2204NovartisA Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma1/2CCpalliative therapy, second line, with genetic FGFR-alteration
BAY86-9766 BayerRefametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)2HCCpalliative therapy, first line, Kras-mutated patients
ResorceBayerStudy with Regorafenib for patients with advanced HCC after Sorafenib3HCCpalliative therapy, second line (after Sorafenib)